SlideShare a Scribd company logo
1 of 19
MUHAMMED SHARKY . M.Pharm
Department of Pharmacy Practice
What is ICH?
ICH is a joint initiative involving both regulators and
research-based industry representatives of the EU,
Japan and the US in scientific and technical
discussions of the testing procedures required to
assess and ensure the safety, quality and efficacy of
medicines.
What does ICH stand for
The complete name of ICH is the “International
Conference on Harmonization of Technical
Requirements for Registration of Pharmaceuticals
for Human Use”.
 Structure of ICH
 ICH is a joint initiative involving both regulators and industry
as equal partners in the scientific and technical discussions of
the testing procedures which are required to ensure and
assess the safety, quality and efficacy of medicines.
 The focus of ICH has been on the technical requirements for
medicinal products containing new drugs. The vast majority
those new drugs and medicines are developed in Western
Europe, Japan and the United States of America.
 The Observers are WHO, EFTA, and Canada (represented by Health
Canada). This important group of non-voting members acts as a link
between the ICH and non-ICH countries and regions.
 ICH is operated via the ICH Steering Committee, which is supported by ICH
Coordinators and the ICH Secretariat.
ICH PARTIES
EURO
PEAN
COM
MISSI
ON/U
NION
EUROPEAN
FEDERATION
OF
PHARMACE
UTICAL
INDUSTRIES
AND
ASSOCIATIO
N
MINI
STRY
OF
HEAL
TH
LABO
UR
AND
WELF
ARE
JAPAN
PHARMACEUTI
CAL
MANUFACTUR
ER
ASSOCIATION
US
FOOD
AND
DRUG
ADMINI
STRATIO
N
PHARMA
CEUTICA
L
RESEARC
H AND
MANUFA
CTURER
S OF
AMERIC
A
 ICH Guidelines
 The ICH Topics are divided into four major categories and ICH Topic
are assigned according to these categories.
FOOD AND DRUG ADMINISTRATION
What Does the FDA Regulate?
 Food (with Agriculture Department)
 Drugs
 Biologics
 Medical Devices
 Cosmetics
 Anything That Produces Dangerous
Radiation
 25% of the Consumer Dollar
Prescription Drug Regulation
 Good Old Days
 In the Early 1900s You Could Get Anything You
Wanted
 No Concern for People Poisoning Themselves
 Few Effective Drugs
 Limited Rationale for Physician Supervision
 Harrison Narcotics Act
 Heroin Was the Hero Drug Because It Saved
People From Morphine
Getting a Drug Approved
 Isolate or Synthesize the Agent
 Many are Biologicals
 Cyclosporin
 Tamoxifen
 Structure Activity Design
 Genetic Engineering
 Do Animal or in Vitro Studies to Determine
Activity
 Apply for an Investigational New Drug (Ind)
Permit
Clinical Trials
 Phase I
 What are the side effects?
 Is it safe enough to test?
 Phase II
 Does it work at all?
 What is the dosage range?
 Phase III
 Is it better than placebo?
 Is it better than other treatments?
 What are the side-effects
Conflicts in Clinical Trials
 Life Saving Drugs
 Patients want a cure
 Drugs probably do not work
 What if the drug is available outside the trial?
 Do you quit a drug that works to get on the
trial?
 What if the patient Lies?
 Non-Life Saving Drugs
 Pay the subjects?
 Docs get paid by the patient
 Companies want positive results
Submit for FDA Approval
 Clinical Trials Can Take Years
 Very Expensive >>$100,000,000
 Most Drugs are Not Approved
 Labeling is Key to Approval
 Narrow Use allows More Dangerous
Drugs
 Broader Use Means More Money
OTC Drugs
 Labeling Is the Key
 Directions for Safe Use
 Recognize Complications
 Recognize Contraindications
 X-OTC Switch
 Why?
 When?
Controlled Substances
 Drug Enforcement Administration (DEA)
 What Are the 5 Schedules?
 I High Potential for Abuse and No Currently
Accepted Medical Use (in the Us) - Heroin
 II High Potential for Abuse but a Medical Use
 III Moderate Potential for Abuse
 IV Low Potential for Abuse
 V Lowest Potential for Abuse
 Constitutional Right to Do Dope?
Post-Market Surveillance
 Clinical Trials Are Limited in Time and Scope
 Many Serious Side-effects Cannot be Detected
in Trials
 Dangerous to Include Pregnant Women, so no
tetragons are detected
 Docs are Supposed to Report Side-effects
 Not always very effective
 Large Scale Trials Should Continue
 Who will fund them?
 Drug Companies do not want to undermine
their products
Regulatory Requirements as per ICH FDA
Regulatory Requirements as per ICH FDA

More Related Content

What's hot

U.S. -- History of Regulation
U.S. -- History of RegulationU.S. -- History of Regulation
U.S. -- History of RegulationMichael Swit
 
Qui Tam: Off Label Drug Marketing [Data Snapshot]
Qui Tam: Off Label Drug Marketing [Data Snapshot]Qui Tam: Off Label Drug Marketing [Data Snapshot]
Qui Tam: Off Label Drug Marketing [Data Snapshot]lawsuitlegal
 
Post marketing surveilance, outsourcing BA and BE to CRO
Post marketing surveilance, outsourcing BA and BE to CROPost marketing surveilance, outsourcing BA and BE to CRO
Post marketing surveilance, outsourcing BA and BE to CROJahnabi Sarmah
 
Detection of Counterfeit Drugs and Other Products
Detection of Counterfeit Drugs and Other ProductsDetection of Counterfeit Drugs and Other Products
Detection of Counterfeit Drugs and Other ProductsNancy Sperling
 
How to access and process FDA drug approval packages for use in research
How to access and process FDA drug approval packages for use in researchHow to access and process FDA drug approval packages for use in research
How to access and process FDA drug approval packages for use in researchErick Turner
 
Counterfeit drugs: what a doctor should know
Counterfeit drugs: what a doctor should knowCounterfeit drugs: what a doctor should know
Counterfeit drugs: what a doctor should knowMark Davison
 
Orphan Drugs – the Challenges and Benefits of Navigating FDA’s Regime Governi...
Orphan Drugs – the Challenges and Benefits of Navigating FDA’s Regime Governi...Orphan Drugs – the Challenges and Benefits of Navigating FDA’s Regime Governi...
Orphan Drugs – the Challenges and Benefits of Navigating FDA’s Regime Governi...Michael Swit
 
Introduction to pharmacovigilance
Introduction to pharmacovigilanceIntroduction to pharmacovigilance
Introduction to pharmacovigilanceNahla Amin
 
Top Trends in Orphan Drugs
Top Trends in Orphan DrugsTop Trends in Orphan Drugs
Top Trends in Orphan DrugsBill Smith
 
Ch 8. laws governing the practice of pharmacy
Ch 8. laws governing the practice of pharmacyCh 8. laws governing the practice of pharmacy
Ch 8. laws governing the practice of pharmacyUniversity of Gondar
 
Orphan Drugs
Orphan DrugsOrphan Drugs
Orphan DrugsANCY JOSE
 
Off-label Use of Medications for COVID-19 Treatment
Off-label  Use of Medications for COVID-19 Treatment Off-label  Use of Medications for COVID-19 Treatment
Off-label Use of Medications for COVID-19 Treatment Belachew Weldegebriel
 

What's hot (20)

U.S. -- History of Regulation
U.S. -- History of RegulationU.S. -- History of Regulation
U.S. -- History of Regulation
 
Qui Tam: Off Label Drug Marketing [Data Snapshot]
Qui Tam: Off Label Drug Marketing [Data Snapshot]Qui Tam: Off Label Drug Marketing [Data Snapshot]
Qui Tam: Off Label Drug Marketing [Data Snapshot]
 
Post marketing surveilance, outsourcing BA and BE to CRO
Post marketing surveilance, outsourcing BA and BE to CROPost marketing surveilance, outsourcing BA and BE to CRO
Post marketing surveilance, outsourcing BA and BE to CRO
 
Detection of Counterfeit Drugs and Other Products
Detection of Counterfeit Drugs and Other ProductsDetection of Counterfeit Drugs and Other Products
Detection of Counterfeit Drugs and Other Products
 
Orphan Drugs
Orphan DrugsOrphan Drugs
Orphan Drugs
 
How to access and process FDA drug approval packages for use in research
How to access and process FDA drug approval packages for use in researchHow to access and process FDA drug approval packages for use in research
How to access and process FDA drug approval packages for use in research
 
Orphan Drugs
Orphan DrugsOrphan Drugs
Orphan Drugs
 
Counterfeit drugs: what a doctor should know
Counterfeit drugs: what a doctor should knowCounterfeit drugs: what a doctor should know
Counterfeit drugs: what a doctor should know
 
MHRA
MHRAMHRA
MHRA
 
Orphan Drugs – the Challenges and Benefits of Navigating FDA’s Regime Governi...
Orphan Drugs – the Challenges and Benefits of Navigating FDA’s Regime Governi...Orphan Drugs – the Challenges and Benefits of Navigating FDA’s Regime Governi...
Orphan Drugs – the Challenges and Benefits of Navigating FDA’s Regime Governi...
 
Introduction to pharmacovigilance
Introduction to pharmacovigilanceIntroduction to pharmacovigilance
Introduction to pharmacovigilance
 
Top Trends in Orphan Drugs
Top Trends in Orphan DrugsTop Trends in Orphan Drugs
Top Trends in Orphan Drugs
 
Orphan drugs
Orphan drugsOrphan drugs
Orphan drugs
 
Inside the FDA
Inside the FDAInside the FDA
Inside the FDA
 
Counterfeit medicine
Counterfeit medicineCounterfeit medicine
Counterfeit medicine
 
Off label use of drugs
Off label use of drugsOff label use of drugs
Off label use of drugs
 
Ch 8. laws governing the practice of pharmacy
Ch 8. laws governing the practice of pharmacyCh 8. laws governing the practice of pharmacy
Ch 8. laws governing the practice of pharmacy
 
Orphan Drugs
Orphan DrugsOrphan Drugs
Orphan Drugs
 
Orphan Drugs
Orphan DrugsOrphan Drugs
Orphan Drugs
 
Off-label Use of Medications for COVID-19 Treatment
Off-label  Use of Medications for COVID-19 Treatment Off-label  Use of Medications for COVID-19 Treatment
Off-label Use of Medications for COVID-19 Treatment
 

Similar to Regulatory Requirements as per ICH FDA

Regulatory authorities of copyright liasion
Regulatory authorities of copyright liasionRegulatory authorities of copyright liasion
Regulatory authorities of copyright liasionRAMZAHASHMI
 
Clinical trials ppt. Dr. Zubair Ali
Clinical trials ppt. Dr. Zubair AliClinical trials ppt. Dr. Zubair Ali
Clinical trials ppt. Dr. Zubair AliDr. Zubair Ali
 
PV Interview Preparation Questions Part-1
PV Interview Preparation Questions Part-1PV Interview Preparation Questions Part-1
PV Interview Preparation Questions Part-1ClinosolIndia
 
Pharmacovigilance Interview Question Part 1
Pharmacovigilance Interview Question Part 1Pharmacovigilance Interview Question Part 1
Pharmacovigilance Interview Question Part 1ClinosolIndia
 
MHRA and USFDA simultaneously data
MHRA and USFDA simultaneously dataMHRA and USFDA simultaneously data
MHRA and USFDA simultaneously data66VaibhavWaghchaure
 
COMMON REGULATORY AFFAIRS JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated in 2022!
COMMON REGULATORY AFFAIRS JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated in 2022!COMMON REGULATORY AFFAIRS JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated in 2022!
COMMON REGULATORY AFFAIRS JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated in 2022!Pristyn Research Solutions
 
Hanson 10e Pp Ts Ch03
Hanson 10e Pp Ts Ch03Hanson 10e Pp Ts Ch03
Hanson 10e Pp Ts Ch03Bryan
 
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries  Unethical Practice Or A Product Of N...Clinical Trials In Developing Countries  Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...Dr Aneek Gupta
 
Chapter 19Clinical Trials Clinical TrialsThe history
Chapter 19Clinical Trials Clinical TrialsThe history Chapter 19Clinical Trials Clinical TrialsThe history
Chapter 19Clinical Trials Clinical TrialsThe history EstelaJeffery653
 
Quality assurance process final
Quality assurance process finalQuality assurance process final
Quality assurance process finalRahibikram Thapa
 
Quality assurance process final
Quality assurance process finalQuality assurance process final
Quality assurance process finalKshitiz Thapa
 
Drug discovery and development
Drug discovery and developmentDrug discovery and development
Drug discovery and developmentSujith Thokala
 
Introduction to Regulatory Affairs - Pauwels Consulting Academy
Introduction to Regulatory Affairs  - Pauwels Consulting AcademyIntroduction to Regulatory Affairs  - Pauwels Consulting Academy
Introduction to Regulatory Affairs - Pauwels Consulting AcademyPauwels Consulting
 
Regulatory Requirements For New Drug Approval
Regulatory Requirements For New Drug ApprovalRegulatory Requirements For New Drug Approval
Regulatory Requirements For New Drug ApprovalShagufta Farooqui
 
regulaotryauthorities-160426054815.pdf
regulaotryauthorities-160426054815.pdfregulaotryauthorities-160426054815.pdf
regulaotryauthorities-160426054815.pdfVhuii
 
Regulatory authorities (US-FDA, WHO and ICH)
Regulatory authorities (US-FDA, WHO and ICH)Regulatory authorities (US-FDA, WHO and ICH)
Regulatory authorities (US-FDA, WHO and ICH)Sagar Savale
 

Similar to Regulatory Requirements as per ICH FDA (20)

Industry and fda laision &
Industry and fda laision &Industry and fda laision &
Industry and fda laision &
 
Regulatory authorities of copyright liasion
Regulatory authorities of copyright liasionRegulatory authorities of copyright liasion
Regulatory authorities of copyright liasion
 
Clinical trials ppt. Dr. Zubair Ali
Clinical trials ppt. Dr. Zubair AliClinical trials ppt. Dr. Zubair Ali
Clinical trials ppt. Dr. Zubair Ali
 
PV Interview Preparation Questions Part-1
PV Interview Preparation Questions Part-1PV Interview Preparation Questions Part-1
PV Interview Preparation Questions Part-1
 
Pharmacovigilance Interview Question Part 1
Pharmacovigilance Interview Question Part 1Pharmacovigilance Interview Question Part 1
Pharmacovigilance Interview Question Part 1
 
MHRA and USFDA simultaneously data
MHRA and USFDA simultaneously dataMHRA and USFDA simultaneously data
MHRA and USFDA simultaneously data
 
COMMON REGULATORY AFFAIRS JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated in 2022!
COMMON REGULATORY AFFAIRS JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated in 2022!COMMON REGULATORY AFFAIRS JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated in 2022!
COMMON REGULATORY AFFAIRS JOB INTERVIEW QUESTIONS WITH ANSWERS-Updated in 2022!
 
Chapter 3
Chapter 3Chapter 3
Chapter 3
 
Hanson 10e Pp Ts Ch03
Hanson 10e Pp Ts Ch03Hanson 10e Pp Ts Ch03
Hanson 10e Pp Ts Ch03
 
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries  Unethical Practice Or A Product Of N...Clinical Trials In Developing Countries  Unethical Practice Or A Product Of N...
Clinical Trials In Developing Countries Unethical Practice Or A Product Of N...
 
Chapter 19Clinical Trials Clinical TrialsThe history
Chapter 19Clinical Trials Clinical TrialsThe history Chapter 19Clinical Trials Clinical TrialsThe history
Chapter 19Clinical Trials Clinical TrialsThe history
 
Ethics chapter
Ethics chapterEthics chapter
Ethics chapter
 
Quality assurance process final
Quality assurance process finalQuality assurance process final
Quality assurance process final
 
Quality assurance process final
Quality assurance process finalQuality assurance process final
Quality assurance process final
 
Drug discovery and development
Drug discovery and developmentDrug discovery and development
Drug discovery and development
 
Introduction to Regulatory Affairs - Pauwels Consulting Academy
Introduction to Regulatory Affairs  - Pauwels Consulting AcademyIntroduction to Regulatory Affairs  - Pauwels Consulting Academy
Introduction to Regulatory Affairs - Pauwels Consulting Academy
 
Pharmacovigilance: A review
Pharmacovigilance: A reviewPharmacovigilance: A review
Pharmacovigilance: A review
 
Regulatory Requirements For New Drug Approval
Regulatory Requirements For New Drug ApprovalRegulatory Requirements For New Drug Approval
Regulatory Requirements For New Drug Approval
 
regulaotryauthorities-160426054815.pdf
regulaotryauthorities-160426054815.pdfregulaotryauthorities-160426054815.pdf
regulaotryauthorities-160426054815.pdf
 
Regulatory authorities (US-FDA, WHO and ICH)
Regulatory authorities (US-FDA, WHO and ICH)Regulatory authorities (US-FDA, WHO and ICH)
Regulatory authorities (US-FDA, WHO and ICH)
 

Recently uploaded

Student login on Anyboli platform.helpin
Student login on Anyboli platform.helpinStudent login on Anyboli platform.helpin
Student login on Anyboli platform.helpinRaunakKeshri1
 
Interactive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationInteractive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationnomboosow
 
How to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxHow to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxmanuelaromero2013
 
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdfSoniaTolstoy
 
Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Celine George
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactPECB
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdfQucHHunhnh
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxpboyjonauth
 
A Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformA Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformChameera Dedduwage
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdfssuser54595a
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactdawncurless
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...EduSkills OECD
 
URLs and Routing in the Odoo 17 Website App
URLs and Routing in the Odoo 17 Website AppURLs and Routing in the Odoo 17 Website App
URLs and Routing in the Odoo 17 Website AppCeline George
 
CARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxCARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxGaneshChakor2
 
Introduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher EducationIntroduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher Educationpboyjonauth
 

Recently uploaded (20)

Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
 
Student login on Anyboli platform.helpin
Student login on Anyboli platform.helpinStudent login on Anyboli platform.helpin
Student login on Anyboli platform.helpin
 
Interactive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communicationInteractive Powerpoint_How to Master effective communication
Interactive Powerpoint_How to Master effective communication
 
How to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptxHow to Make a Pirate ship Primary Education.pptx
How to Make a Pirate ship Primary Education.pptx
 
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdfBASLIQ CURRENT LOOKBOOK  LOOKBOOK(1) (1).pdf
BASLIQ CURRENT LOOKBOOK LOOKBOOK(1) (1).pdf
 
Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17Advanced Views - Calendar View in Odoo 17
Advanced Views - Calendar View in Odoo 17
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
 
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptxINDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
 
Staff of Color (SOC) Retention Efforts DDSD
Staff of Color (SOC) Retention Efforts DDSDStaff of Color (SOC) Retention Efforts DDSD
Staff of Color (SOC) Retention Efforts DDSD
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
 
Introduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptxIntroduction to AI in Higher Education_draft.pptx
Introduction to AI in Higher Education_draft.pptx
 
A Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy ReformA Critique of the Proposed National Education Policy Reform
A Critique of the Proposed National Education Policy Reform
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impact
 
Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1
 
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
Presentation by Andreas Schleicher Tackling the School Absenteeism Crisis 30 ...
 
URLs and Routing in the Odoo 17 Website App
URLs and Routing in the Odoo 17 Website AppURLs and Routing in the Odoo 17 Website App
URLs and Routing in the Odoo 17 Website App
 
CARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptxCARE OF CHILD IN INCUBATOR..........pptx
CARE OF CHILD IN INCUBATOR..........pptx
 
Mattingly "AI & Prompt Design: The Basics of Prompt Design"
Mattingly "AI & Prompt Design: The Basics of Prompt Design"Mattingly "AI & Prompt Design: The Basics of Prompt Design"
Mattingly "AI & Prompt Design: The Basics of Prompt Design"
 
Introduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher EducationIntroduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher Education
 

Regulatory Requirements as per ICH FDA

  • 1. MUHAMMED SHARKY . M.Pharm Department of Pharmacy Practice
  • 2. What is ICH? ICH is a joint initiative involving both regulators and research-based industry representatives of the EU, Japan and the US in scientific and technical discussions of the testing procedures required to assess and ensure the safety, quality and efficacy of medicines.
  • 3. What does ICH stand for The complete name of ICH is the “International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use”.
  • 4.  Structure of ICH  ICH is a joint initiative involving both regulators and industry as equal partners in the scientific and technical discussions of the testing procedures which are required to ensure and assess the safety, quality and efficacy of medicines.  The focus of ICH has been on the technical requirements for medicinal products containing new drugs. The vast majority those new drugs and medicines are developed in Western Europe, Japan and the United States of America.
  • 5.  The Observers are WHO, EFTA, and Canada (represented by Health Canada). This important group of non-voting members acts as a link between the ICH and non-ICH countries and regions.  ICH is operated via the ICH Steering Committee, which is supported by ICH Coordinators and the ICH Secretariat.
  • 7.  ICH Guidelines  The ICH Topics are divided into four major categories and ICH Topic are assigned according to these categories.
  • 8. FOOD AND DRUG ADMINISTRATION
  • 9. What Does the FDA Regulate?  Food (with Agriculture Department)  Drugs  Biologics  Medical Devices  Cosmetics  Anything That Produces Dangerous Radiation  25% of the Consumer Dollar
  • 10. Prescription Drug Regulation  Good Old Days  In the Early 1900s You Could Get Anything You Wanted  No Concern for People Poisoning Themselves  Few Effective Drugs  Limited Rationale for Physician Supervision  Harrison Narcotics Act  Heroin Was the Hero Drug Because It Saved People From Morphine
  • 11. Getting a Drug Approved  Isolate or Synthesize the Agent  Many are Biologicals  Cyclosporin  Tamoxifen  Structure Activity Design  Genetic Engineering  Do Animal or in Vitro Studies to Determine Activity  Apply for an Investigational New Drug (Ind) Permit
  • 12. Clinical Trials  Phase I  What are the side effects?  Is it safe enough to test?  Phase II  Does it work at all?  What is the dosage range?  Phase III  Is it better than placebo?  Is it better than other treatments?  What are the side-effects
  • 13. Conflicts in Clinical Trials  Life Saving Drugs  Patients want a cure  Drugs probably do not work  What if the drug is available outside the trial?  Do you quit a drug that works to get on the trial?  What if the patient Lies?  Non-Life Saving Drugs  Pay the subjects?  Docs get paid by the patient  Companies want positive results
  • 14. Submit for FDA Approval  Clinical Trials Can Take Years  Very Expensive >>$100,000,000  Most Drugs are Not Approved  Labeling is Key to Approval  Narrow Use allows More Dangerous Drugs  Broader Use Means More Money
  • 15. OTC Drugs  Labeling Is the Key  Directions for Safe Use  Recognize Complications  Recognize Contraindications  X-OTC Switch  Why?  When?
  • 16. Controlled Substances  Drug Enforcement Administration (DEA)  What Are the 5 Schedules?  I High Potential for Abuse and No Currently Accepted Medical Use (in the Us) - Heroin  II High Potential for Abuse but a Medical Use  III Moderate Potential for Abuse  IV Low Potential for Abuse  V Lowest Potential for Abuse  Constitutional Right to Do Dope?
  • 17. Post-Market Surveillance  Clinical Trials Are Limited in Time and Scope  Many Serious Side-effects Cannot be Detected in Trials  Dangerous to Include Pregnant Women, so no tetragons are detected  Docs are Supposed to Report Side-effects  Not always very effective  Large Scale Trials Should Continue  Who will fund them?  Drug Companies do not want to undermine their products